Sagent Pharma Announces Termporary Importation of Sodium Bicarbonate Injection
Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) today announced that due to the current critical shortage of Sodium Bicarbonate Injection, USP in the United States market, Sagent, in cooperation with the U.S. Food and Drug Administration ("FDA"), has initiated the temporary importation into the U.S. of a non-FDA approved 8.4% Sodium Bicarbonate Injection (1 mEQ/mL) from Phebra Pty Ltd., an Australian manufacturer. Please refer to the Dear Healthcare Provider Letter, posted on the FDA website, for further information about availability of supply.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.